The high prevalence of neurodegenerative diseases is an unintended consequence of the
high longevity of the population, together with the lack of effective preventive and therapeutic …

Multiple studies describe prodromal, nonmotor dysfunctions that affect the quality of life of
patients who subsequently develop Parkinson's disease (PD). These prodromal …

Tricin, a natural nontoxic flavonoid distributed in grasses and euphorbia plants, has been
reported to scavenge free radicals, possess anti-inflammatory and antioxidative effects …

Although striatal delivery of three critical genes for dopamine synthesis by viruses is a
potential clinical approach for treating Parkinson's disease (PD), the approach makes it …

Aims Parkinson's disease (PD) remains a substantial clinical challenge due to the
progressive loss of midbrain dopaminergic (DA) neurons in nigrostriatal pathway. In this …

The facilitation of corticostriatal transmission is modulated by the pharmacological inhibition
of striatal phosphodiesterase 10A (PDE10A). Since L-DOPA-induced dyskinesia is …

Mitochondria, the energy hubs of the cell, are progressively becoming attractive targets in
the search for potent therapeutics against neurodegenerative diseases. The pivotal role of …

Pain in Parkinson's disease (PD) has been validated as one of the major non-motor
dysfunctions affecting the quality of life and subsequent rehabilitation. In the present study …

Levodopa (L‐DOPA) is the classical gold standard treatment for Parkinson's disease.
However, its chronic administration can lead to the development of L‐DOPA‐induced …

The pathogenesis of Parkinson's disease (PD) remains unclear. Among the pathological
manifestations is the progressive degeneration of the nigrostriatal dopaminergic pathway …